Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q2 2021 · 10-Q
Revenue$1.82M$1.82M−10.9% vs Q2 2020 Net Income-$18.16M-$18.16MN/M vs Q2 2020 EPS Diluted-$0.34-$0.34N/M vs Q2 2020 Operating Income-$18,006,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-987.2%−430.9 pt vs Q2 2020
Net margin-995.7%−428.9 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 5, 2021 · 36 d after period end